Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions

doi:10.19803/j.1672-8629.20220630

Abstract

Abstract: Vancomycin is a glycopeptide antibiotic, which is widely used in clinic. It is one of the most effective antibiotics for drug-resistant gram-positive bacterial infections. It can control refractory infections, but may also induce a variety of side effects. For example, the incidence of anaphylactoid reactions represented by Red Man Syndrome (RMS) and Ig-E mediated hypersensitivity reactions is high, and the clinical consequences are serious. Moreover, the clinical manifestations and diagnostic methods of the two are similar, which requires quick identification and intervention. However, the treatment methods following the two types of reactions vary and whether vancomycin can continue to be used depends on the conditions of patients, so the prevention, diagnosis and differential diagnosis of the two types of side effects are very important. With regard to the similarities and differences between RMS and Ig-E mediated hypersensitivity, this article reviews the related literature and outlines the clinical manifestations, differential diagnosis, identification of high-risk populations, prevention methods, and treatments.

Key words: vancomycin, red man syndrome, anaphylactoid reaction, Ig-E mediated hypersensitivity reaction, anaphylaxis, adverse drug reactions

CLC Number:

R978
R994

ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.

References

[1] ROTHENBERG HJ.Anaphylactoid reaction to vancomycin[J]. J Am Med Assoc, 1959, 171: 1101-1102.
[2] GARRELTS JC, PETERIE JD.Vancomycin and the“red man's syndrome”[J]. N Engl J Med, 1985, 312: 245.
[3] ARROYO-MERCADO F, KHUDYAKOV A, CHAWLA GS, et al.Red man syndrome with oral vancomycin: a case report[J]. Am J Med Case Rep, 2019, 7(1): 16-17.
[4] DEWEESE R, SLAVENS J, BARUA A, et al.Vancomycin-induced eosinophilic peritonitis[J]. Am J Health Syst Pharm, 2016, 73(9): e243-e246.
[5] ALVAREZ-ARANGO S, OGUNWOLE SM, SEQUIST TD, et al.Vancomycin infusion reaction - moving beyond “red man syndrome”[J]. N Engl J Med, 2021, 384(14): 1283-1286.
[6] APUYA J, KLEIN EF.Stridor accompanying red man's syndrome following perioperative administration of vancomycin[J]. J Clin Anesth, 2009, 21(8): 606-608.
[7] ALVAREZ-ARANGO S, YERNENI S, TANG O, et al.Vancomycin hypersensitivity reactions documented in electronic health records[J]. J Allergy Clin Immunol Pract, 2021, 9(2): 906-912.
[8] POLK RE, HEALY DP, SCHWARTZ LB, et al.Vancomycin and the red-man syndrome: pharmacodynamics of histamine release[J]. J Infect Dis, 1988, 157(3): 502-507.
[9] HEALY DP, SAHAI JV, FULLER SH, et al.Vancomycin-induced histamine release and “red man syndrome”: comparison of 1 and 2 hour infusions[J]. Antimicrob Agents Chemother, 1990, 34(4): 5504.
[10] POLK RE, ISRAEL D, WANG J, et al.Vancomycin skin tests and prediction of “red man syndrome” in healthy volunteers[J]. Antimicrob Agents Chemother, 1993, 37(10): 2139-2143.
[11] BROYLES AD, BANERJI A, BARMETTLER S, et al.Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs[J]. J Allergy Clin Immunol Pract, 2020, 8(9S): S16-S116.
[12] VITTE J, AMADEI L, GOUITAA M, et al.Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: an observational study[J]. Allergy, 2019, 74(6): 1157-1165.
[13] XU Y, CHEN G. Mast cell and autoimmune diseases[J/OL]. [2022-10-01]. http://dx.doi.org/10.1155/2015/246126.
[14] RENZ CL, THURN JD, FINN HA, et al.Oral antihistamines reduce the side effects from rapid vancomycin infusion[J]. Anesth Analg, 1998, 87(3): 681-685.
[15] VALENT P, AKIN C, AROCK M, et al.Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal[J]. Int Arch Allergy Immuno, 2012, 157(3): 215-225.
[16] ANICETO V, DIAS MM, MELO JML, et al.Serum baseline tryptase level as a marker for the severity of anaphylaxis[J]. Int Arch Allergy Immunol, 2019, 179(3): 201-208.
[17] OTANI IM, KUHLEN JL JR, BLUMENTHAL KG, et al.A role for vancomycin epicutaneous skin testing in the evaluation of perioperative anaphylaxis[J]. J Allergy Clin Immunol Pract, 2015, 3(6): 984-985.
[18] MYERS AL, GAEDIGK A, DAI H, et al.Defining risk factors for red man syndrome in children and adults[J]. Pediatr Infect Dis J, 2012, 31(5): 464-468.
[19] NEWFIELD P, ROIZEN MF.Hazards of rapid administration of vancomycin[J]. Ann Intern Med, 1979, 91(4): 581.
[20] SIVAGNANAM S, DELEU D.Red man syndrome[J]. Crit Care, 2003, 7(2): 119-120.
[21] LIN SK, MULIERI KM, ISHMAEL FT.Characterization of vancomycin reactions and linezolid utilization in the pediatric population[J]. J Allergy Clin Immunol Pract, 2017, 5(3): 750-756.
[22] MCNEIL BD, PUNDIR P, MEEKER S, et al.Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J]. Nature, 2015, 519(7542): 237-241.
[23] GAUDENZIO N, SIBILANO R, MARICHAL T, et al.Different activation signals induce distinct mast cell degranulation strategies[J]. J Clin Invest, 2016, 126(10): 3981-3998.
[24] MCNEIL BD, PUNDIR P, MEEKER S, et al.Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J]. Nature, 2015, 519(7542): 237-241.
[25] BABINA M, GUHL S, ARTUC M, et al.Allergic FcεRI- and pseudo-allergic MRGPRX2-triggered mast cell activation routes are independent and inversely regulated by SCF[J]. Allergy, 2017, 73(1): 256-260.